shutterstock_664142593_jonathan_weiss
Jonathan Weiss / Shutterstock.com
3 June 2019Americas

Eli Lilly secures exclusive rights to chronic pain treatment

American pharmaceutical company Eli Lilly has secured an exclusive licence for a non-opioid, non-addictive chronic pain treatment from Boston-based biotech company Centrexion Therapeutics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
23 May 2019   Eli Lilly has released a generic insulin injection at half of the list price of its identical branded medicine to the US market.
Americas
6 June 2019   San Francisco-based biotech company Atomwise could be set to receive up to $1 million per target in milestone payments following a partnership agreement with Eli Lilly.
Big Pharma
16 January 2020   Global healthcare provider Eli Lilly has agreed to buy Dermira, a biopharmaceutical company, for $1.1 billion, giving it access to a late-stage atopic dermatitis drug and allowing it to challenge Sanofi’s already fully-licenced dupilumab.

More on this story

Americas
23 May 2019   Eli Lilly has released a generic insulin injection at half of the list price of its identical branded medicine to the US market.
Americas
6 June 2019   San Francisco-based biotech company Atomwise could be set to receive up to $1 million per target in milestone payments following a partnership agreement with Eli Lilly.
Big Pharma
16 January 2020   Global healthcare provider Eli Lilly has agreed to buy Dermira, a biopharmaceutical company, for $1.1 billion, giving it access to a late-stage atopic dermatitis drug and allowing it to challenge Sanofi’s already fully-licenced dupilumab.

More on this story

Americas
23 May 2019   Eli Lilly has released a generic insulin injection at half of the list price of its identical branded medicine to the US market.
Americas
6 June 2019   San Francisco-based biotech company Atomwise could be set to receive up to $1 million per target in milestone payments following a partnership agreement with Eli Lilly.
Big Pharma
16 January 2020   Global healthcare provider Eli Lilly has agreed to buy Dermira, a biopharmaceutical company, for $1.1 billion, giving it access to a late-stage atopic dermatitis drug and allowing it to challenge Sanofi’s already fully-licenced dupilumab.